Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Alimera Sciences develops patient access scheme for Iluvien in U.K.

Dec. 3, 2012

No Comments

InSite Vision completes enrollment in phase III BromSite study

Dec. 3, 2012

No Comments

U.K.'s NICE selects ThromboGenics' Jetrea for single technology appraisal

Nov. 28, 2012

No Comments

Amakem patents new ROCK-II inhibitors

Nov. 28, 2012

No Comments

Eylea for wet AMD approved in E.U., launched in Japan

Nov. 27, 2012

No Comments

Santen files for DE-114 approval in Japan

Nov. 27, 2012

No Comments

Oxford BioMedica provides update on ocular gene therapy candidates

Nov. 21, 2012

No Comments

Allergan patents new S1P1 receptor agonists

Nov. 15, 2012

No Comments

Advanced Cell Technology reports interim clinical data on hESC-derived RPE cells

Nov. 13, 2012

No Comments

Novartis files supplemental NDA for Neoral in Japan

Nov. 13, 2012

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Ocular
RSS

Alimera Sciences develops patient access scheme for Iluvien in U.K.

InSite Vision completes enrollment in phase III BromSite study

U.K.'s NICE selects ThromboGenics' Jetrea for single technology appraisal

Amakem patents new ROCK-II inhibitors

Eylea for wet AMD approved in E.U., launched in Japan

Santen files for DE-114 approval in Japan

Oxford BioMedica provides update on ocular gene therapy candidates

Allergan patents new S1P1 receptor agonists

Advanced Cell Technology reports interim clinical data on hESC-derived RPE cells

Novartis files supplemental NDA for Neoral in Japan

Today's news in brief

Today's news in brief

Enhanced Cognition: Lewy body dementia phase II pumps stock

Experimental mRNA gene therapy suppresses preeclampsia in mice

Probing bidirectional cancer-autoimmune link can yield new targets

Ocular RSS

Ocular
RSS